Ondansetron Accordpharma

Ondansetron, the active ingredient in Ondansetron Accordpharma, is a 5-HT3 receptor antagonist presented as a tablet for oral use. It treats and prevents nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients. GNH USA supplies Ondansetron Accordpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Accordpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ondansetron Accordpharma is a selective 5‑HT3 receptor antagonist used to manage nausea and vomiting pathways in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: Reduces the frequency and severity of acute and delayed episodes. - Radiation‑induced nausea and vomiting: Helps control nausea during and after radiotherapy. - Post‑operative nausea and vomiting: Prevents vomiting following surgical procedures. - Pregnancy‑related hyperemesis gravis: Alleviates severe nausea and vomiting when other treatments are insufficient. - Anticipatory nausea: Decreases nausea that occurs before chemotherapy in patients with previous experience.

Common Side Effects: - Headache: Mild to moderate headache may occur. - Constipation: Reduced bowel movements are reported. - Diarrhoea: Loose stools can appear. - Fatigue: General tiredness may be experienced. - Dizziness: Light‑headedness or vertigo may be felt.

Serious or Rare Side Effects: - QT prolongation: May cause abnormal heart rhythm. - Severe allergic reaction: Includes rash, itching, swelling, or difficulty breathing. - Serotonin syndrome: Rare but serious condition with agitation, fever, and muscle rigidity. - Hepatic dysfunction: Elevated liver enzymes indicating liver stress. - Cardiac arrhythmia: Irregular heartbeat beyond QT changes.

Ondansetron should be used with caution in patients with known cardiac conditions.

- Cardiac monitoring: Perform ECG monitoring in patients at risk for QT prolongation. - Electrolyte balance: Correct electrolyte abnormalities before initiating therapy. - Drug interactions: Review concomitant medications for potential serotonergic effects. - Pregnancy and lactation: Evaluate risk‑benefit ratio before prescribing. - Renal or hepatic impairment: Adjust dose if necessary based on clinical judgment. - Store at ambient temperature: Keep the tablets in the original packaging.

Ondansetron may interact       

Major   g       i   e

""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""

Moderate  

"""  """""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""

"""  """